Gastro-oesophageal reflux disease (GERD) is a recognised comorbidity in systemic sclerosis. This clinical scenario focuses on patients with systemic sclerosis who also present with GERD, where oesophageal involvement can increase the risk of ulceration and stricture formation.
PPI should be considered for the treatment of SSc-GERD and prevention of oesophageal ulcers and strictures.
The task force acknowledged the need to address gastro-oesophageal reflux disease with PPI treatment at least in first instance and recommended their use in an attempt to control symptoms and prevent oesophageal complications.